Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SRF388 · 1 trial · 1 indication
Summaries of AEs will be based on TEAEs. A TEAE is an AE that emerges or worsens in the period from the first dose of study drug to 30 days after the last dose of study drug (Lead-In Phase).
PFS according to RECIST v1.1 will be evaluated in patients receiving SRF388 in combination with atezolizumab plus bevacizumab compared to placebo in combination with atezolizumab plus bevacizumab (Randomized Phase).
| Arm | Type | Description |
|---|---|---|
| Lead-In | EXPERIMENTAL | A minimum of 6 patients and up to 30 patients will be enrolled in an open-label Lead-In to assess the preliminary safety and tolerability of SRF388 with atezolizumab plus bevacizumab. |
| Arm A: SRF388 in Combination with atezolizumab plus bevacizumab | EXPERIMENTAL | Patients randomized to Arm A will receive SRF388 with atezolizumab plus bevacizumab. |
| Arm B: Placebo in combination with atezolizumab plus bevacizumab | EXPERIMENTAL | Patients randomized to Arm B will receive placebo with atezolizumab plus bevacizumab. |
| Name | Type | Description |
|---|---|---|
| SRF388 | DRUG | SRF388 will be administered by intravenous injection (IV) |
| Atezolizumab | DRUG | Azezolizumab will be administered by IV |
| Bevacizumab | DRUG | Bevacizumab will be administered by IV |
| Placebo | DRUG | Placebo will be administered by IV |
Abbreviated Inclusion Criteria: * ≥ 18 years of age on day of signing informed consent * Unresectable locally advanced or metastatic HCC * No prior systemic treatment for unresectable locally advanced or metastatic HCC * BCLC Stage B or Stage C disease * Child-Pugh Class A disease * ≥ 1 measurable ...
SRF388 is an investigational small molecule being studied for the treatment of Hepatocellular Carcinoma. It is currently in Phase 2 clinical development. In a completed trial, SRF388 was evaluated in combination with atezolizumab and bevacizumab versus placebo in patients with hepatocellular carcinoma.
SRF388 is being developed by Coherus Oncology, Inc., a subsidiary of Coherus BioSciences, which trades under the ticker CHRS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with hepatocellular carcinoma.
SRF388 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 trial testing SRF388 in combination with atezolizumab and bevacizumab for hepatocellular carcinoma has been completed.
SRF388 has been studied in one clinical trial, identified as NCT05359861. This Phase 2 trial, titled 'Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma,' enrolled 30 participants and has been completed.
No, SRF388 is a distinct investigational small molecule. In the clinical trial NCT05359861, SRF388 was tested in combination with atezolizumab and bevacizumab, which are established cancer therapies. SRF388 is not the same drug as either of these agents.